JP7788376B2 - 最適化されたｇｉｐペプチド類縁体 - Google Patents

最適化されたｇｉｐペプチド類縁体

Info

Publication number
JP7788376B2
JP7788376B2 JP2022532697A JP2022532697A JP7788376B2 JP 7788376 B2 JP7788376 B2 JP 7788376B2 JP 2022532697 A JP2022532697 A JP 2022532697A JP 2022532697 A JP2022532697 A JP 2022532697A JP 7788376 B2 JP7788376 B2 JP 7788376B2
Authority
JP
Japan
Prior art keywords
amino acid
gip
seq
peptide
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022532697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505441A5 (https=
JP2023505441A (ja
JPWO2021110845A5 (https=
Inventor
ロースンキーレ，メッテ，マリー
スパール‐ウリッチ，アレクサンダー，ホヴァード
リバー，ディッテ
サンニ，サムラ，ジョーク
Original Assignee
アンタグ セラピューティクス エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by アンタグ セラピューティクス エーピーエス filed Critical アンタグ セラピューティクス エーピーエス
Publication of JP2023505441A publication Critical patent/JP2023505441A/ja
Publication of JP2023505441A5 publication Critical patent/JP2023505441A5/ja
Publication of JPWO2021110845A5 publication Critical patent/JPWO2021110845A5/ja
Priority to JP2025141835A priority Critical patent/JP2025172864A/ja
Application granted granted Critical
Publication of JP7788376B2 publication Critical patent/JP7788376B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022532697A 2019-12-03 2020-12-03 最適化されたｇｉｐペプチド類縁体 Active JP7788376B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025141835A JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EPPCT/EP2019/083506 2019-12-03
EP20179259 2020-06-10
EP20179259.5 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025141835A Division JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Publications (4)

Publication Number Publication Date
JP2023505441A JP2023505441A (ja) 2023-02-09
JP2023505441A5 JP2023505441A5 (https=) 2023-12-12
JPWO2021110845A5 JPWO2021110845A5 (https=) 2023-12-12
JP7788376B2 true JP7788376B2 (ja) 2025-12-18

Family

ID=71083547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022532697A Active JP7788376B2 (ja) 2019-12-03 2020-12-03 最適化されたｇｉｐペプチド類縁体
JP2025141835A Pending JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025141835A Pending JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Country Status (9)

Country Link
US (1) US20250346647A2 (https=)
EP (1) EP4069719A1 (https=)
JP (2) JP7788376B2 (https=)
KR (1) KR20220108064A (https=)
AU (1) AU2020398675A1 (https=)
CA (1) CA3157387A1 (https=)
IL (1) IL293249A (https=)
MX (1) MX2022006737A (https=)
WO (1) WO2021110845A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021212A (ko) * 2021-06-10 2024-02-16 안타그 테라퓨틱스 에이피에스 비만 및 비만-관련 장애의 치료
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
UY40349A (es) * 2022-07-13 2024-01-31 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista dual de glp-1/gip, método de preparación y uso del mismo
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
JP2010500996A (ja) 2006-08-17 2010-01-14 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
JP2011530508A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドのアナログ
JP2011530507A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues
JP2022509568A (ja) 2018-12-03 2022-01-20 アンタグ セラピューティクス エーピーエス 修飾されたｇｉｐペプチド類似体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
JP6228187B2 (ja) * 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
PL3630806T3 (pl) * 2017-05-31 2024-05-13 The University Of Copenhagen Analogi peptydów gip o długotrwałym działaniu
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
JP2010500996A (ja) 2006-08-17 2010-01-14 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
JP2011530508A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドのアナログ
JP2011530507A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues
JP2022509568A (ja) 2018-12-03 2022-01-20 アンタグ セラピューティクス エーピーエス 修飾されたｇｉｐペプチド類似体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IRWIN, N et al.，GIP(Lys16PAL) and GIP(LYS37PAL): Novel Long-Acting Acylated Analogues of Glucose-Dependent Insulinotropic Polypeptide with Improved Antidiabetic Potential，Journal of Medicinal Chemistry，2006年，Vol. 49，pp. 1047-1054
PATHAK, V et al.，Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice，Molecular and Cellular Endocrinology，2015年，Vol. 401，pp. 120-129
PATHAK, V et al.，Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice，Diabetologia，2015年，Vol. 58，pp. 2144-2153

Also Published As

Publication number Publication date
WO2021110845A1 (en) 2021-06-10
EP4069719A1 (en) 2022-10-12
JP2023505441A (ja) 2023-02-09
CA3157387A1 (en) 2021-06-10
KR20220108064A (ko) 2022-08-02
US20250346647A2 (en) 2025-11-13
IL293249A (en) 2022-07-01
JP2025172864A (ja) 2025-11-26
AU2020398675A1 (en) 2022-05-26
CN114761420A (zh) 2022-07-15
US20230416330A1 (en) 2023-12-28
MX2022006737A (es) 2022-06-14

Similar Documents

Publication Publication Date Title
JP7605747B2 (ja) 修飾されたｇｉｐペプチド類似体
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
JP7788376B2 (ja) 最適化されたｇｉｐペプチド類縁体
CN110691788B (zh) 长效gip肽类似物
RU2858286C2 (ru) Оптимизированные пептидные аналоги gip
CN114761420B (zh) 优化的gip肽类似物
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
EA048422B1 (ru) Соединения-коагонисты gip/glp1
HK1169998A1 (en) Gip receptor-active glucagon compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251208

R150 Certificate of patent or registration of utility model

Ref document number: 7788376

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150